Clinical Trials Browser

Suspended × pembrolizumab × Dermatologic × Clear all

NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Phase 1/2 Suspended

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05764395 2024-10-10

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Phase 2 Suspended

Melanoma